WO2002000840A3 - Lyases humaines - Google Patents

Lyases humaines Download PDF

Info

Publication number
WO2002000840A3
WO2002000840A3 PCT/US2001/019166 US0119166W WO0200840A3 WO 2002000840 A3 WO2002000840 A3 WO 2002000840A3 US 0119166 W US0119166 W US 0119166W WO 0200840 A3 WO0200840 A3 WO 0200840A3
Authority
WO
WIPO (PCT)
Prior art keywords
hlya
provides
lyases
human lyases
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/019166
Other languages
English (en)
Other versions
WO2002000840A2 (fr
Inventor
Michael Thornton
Jayalaxmi Ramkumar
Catherine M Tribouley
Henry Yue
Danniel B Nguyen
Monique G Yao
Chandra Patterson
Ameena R Gandhi
Neil Burford
Kavitha Thangavelu
Mariah R Baughn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc filed Critical Incyte Genomics Inc
Priority to EP01944529A priority Critical patent/EP1292685A2/fr
Priority to AU2001266932A priority patent/AU2001266932A1/en
Priority to CA002381338A priority patent/CA2381338A1/fr
Priority to JP2002505956A priority patent/JP2004501632A/ja
Publication of WO2002000840A2 publication Critical patent/WO2002000840A2/fr
Publication of WO2002000840A3 publication Critical patent/WO2002000840A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La présente invention concerne des lyases humaines (HLYA) et des polynucléotides qui identifient et codent HLYA. Par ailleurs, cette invention concerne des vecteurs d'expression, des cellules hôtes, des anticorps, des agonistes et des antagonistes. De plus, cette invention concerne des méthodes diagnostiques, thérapeutiques ou prophylactiques de troubles associés à l'expression aberrante de HLYA.
PCT/US2001/019166 2000-06-23 2001-06-13 Lyases humaines Ceased WO2002000840A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP01944529A EP1292685A2 (fr) 2000-06-23 2001-06-13 Lyases humaines
AU2001266932A AU2001266932A1 (en) 2000-06-23 2001-06-13 Human lyases
CA002381338A CA2381338A1 (fr) 2000-06-23 2001-06-13 Lyases humaines
JP2002505956A JP2004501632A (ja) 2000-06-23 2001-06-13 ヒトリアーゼ

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US21338300P 2000-06-23 2000-06-23
US60/213,383 2000-06-23
US21554400P 2000-06-30 2000-06-30
US60/215,544 2000-06-30
US22281800P 2000-08-04 2000-08-04
US60/222,818 2000-08-04

Publications (2)

Publication Number Publication Date
WO2002000840A2 WO2002000840A2 (fr) 2002-01-03
WO2002000840A3 true WO2002000840A3 (fr) 2002-08-08

Family

ID=27395860

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/019166 Ceased WO2002000840A2 (fr) 2000-06-23 2001-06-13 Lyases humaines

Country Status (5)

Country Link
EP (1) EP1292685A2 (fr)
JP (1) JP2004501632A (fr)
AU (1) AU2001266932A1 (fr)
CA (1) CA2381338A1 (fr)
WO (1) WO2002000840A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002236595A1 (en) * 2000-12-07 2002-06-18 Incyte Genomics, Inc. Enzymes
WO2002053716A2 (fr) * 2001-01-03 2002-07-11 Bayer Aktiengesellschaft Regulation de l'ornithine decarboxylase humaine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988004688A1 (fr) * 1986-12-23 1988-06-30 Howard Florey Institute Of Experimental Physiology Isoenzyme d'anhydrase carbonique
US5972684A (en) * 1997-11-25 1999-10-26 Incyte Pharmaceuticals, Inc. Carbonic anhydrase VIII
WO2000061748A1 (fr) * 1999-04-09 2000-10-19 Human Genome Sciences, Inc. 48 proteines humaines secretees
WO2001062927A2 (fr) * 2000-02-24 2001-08-30 Incyte Genomics Inc Molecules utilisees a des fins diagnostiques et therapeutiques

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988004688A1 (fr) * 1986-12-23 1988-06-30 Howard Florey Institute Of Experimental Physiology Isoenzyme d'anhydrase carbonique
US5972684A (en) * 1997-11-25 1999-10-26 Incyte Pharmaceuticals, Inc. Carbonic anhydrase VIII
WO2000061748A1 (fr) * 1999-04-09 2000-10-19 Human Genome Sciences, Inc. 48 proteines humaines secretees
WO2001062927A2 (fr) * 2000-02-24 2001-08-30 Incyte Genomics Inc Molecules utilisees a des fins diagnostiques et therapeutiques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HEWETT-EMMETT DAVID ET AL: "Functional diversity, conservation, and convergence in the evolution of the alpha-, beta-, and gamma-carbonic anhydrase gene families.", MOLECULAR PHYLOGENETICS AND EVOLUTION, vol. 5, no. 1, 1996, pages 50 - 77, XP002190992, ISSN: 1055-7903 *
LOWE N ET AL: "STRUCTURE AND METHYLATION PATTERNS OF THE GENE ENCODING HUMAN CARBONIC ANHYDRASE I", GENE (AMSTERDAM), vol. 93, no. 2, 1990, pages 277 - 283, XP002190991, ISSN: 0378-1119 *

Also Published As

Publication number Publication date
JP2004501632A (ja) 2004-01-22
AU2001266932A1 (en) 2002-01-08
EP1292685A2 (fr) 2003-03-19
CA2381338A1 (fr) 2002-01-03
WO2002000840A2 (fr) 2002-01-03

Similar Documents

Publication Publication Date Title
WO2001098468A3 (fr) Proteases
WO2003052075A3 (fr) Enzymes
WO2002063005A3 (fr) Molecules associees a des lipides
WO2001096547A3 (fr) Kinases humaines
WO2002018557A3 (fr) Kinases humaines
WO2002008396A3 (fr) Proteases
WO2001060991A3 (fr) Kinases humaines
WO2001051638A3 (fr) Enzymes de metabolisation de medicaments
WO2002004612A3 (fr) Enzymes metabolisant les medicaments
WO2001090334A3 (fr) Enzymes de metabolisation de medicaments
WO2001072777A3 (fr) Facteurs de transcription
WO2001046397A3 (fr) Kinases humaines
WO2003042357A3 (fr) Enzymes
WO2001071004A3 (fr) Proteases
WO2002038744A3 (fr) Protéases
WO2002026950A3 (fr) Transferases
WO2001098471A8 (fr) Phosphodiesterases
WO2001085942A3 (fr) Proteines associees au cytosquelette
WO2001081555A3 (fr) Kinases humaines
WO2001059127A3 (fr) Enzymes metabolisant les medicaments
WO2001079468A3 (fr) Enzymes metabolisant les medicaments
WO2002033099A3 (fr) Kinases humaines
WO2002002757A3 (fr) Adenylyl et guanylyl cyclases
WO2002020736A3 (fr) Proteases
WO2001092527A3 (fr) Regulateurs de l'apoptose

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2381338

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001944529

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10069434

Country of ref document: US

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001944529

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001944529

Country of ref document: EP